RECRUITING

TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to determine the effects of TrueBeam stereotactic body radiosurgery in patients with prostate cancer. The device is designed to concentrate large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal. The purpose of this evaluation is to see if this treatment will help patients with your condition and to evaluate the effect of this treatment on your quality of life over time. Radiosurgery is a non-invasive treatment technique used to treat tumors. Despite the word "surgery" in the name, the technology does not remove the tumor with a surgical knife. Instead, a focused, high-intensity beam of radiation targets the tumor, while minimizing dose to surrounding normal healthy tissue.

Official Title

Prospective Evaluation of TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer: Risk Stratified MonoTherapy Versus RADIOSURGERY Boost

Quick Facts

Study Start:2018-06-05
Study Completion:2026-12-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04552509

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:MALE
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. 1. Prior prostatectomy or cryotherapy of the prostate
  2. 2. Prior radiotherapy to the prostate or lower pelvis
  3. 3. Implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator's opinion.

Contacts and Locations

Study Contact

Linda Chan, MD
CONTACT
562-933-0300
lchan@memorialcare.org

Principal Investigator

Linda Chan, MD
PRINCIPAL_INVESTIGATOR
Memorial Health Services

Study Locations (Sites)

MemorialCare Saddleback Medical Center
Laguna Hills, California, 92653
United States

Collaborators and Investigators

Sponsor: Linda Chan, MD

  • Linda Chan, MD, PRINCIPAL_INVESTIGATOR, Memorial Health Services

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-06-05
Study Completion Date2026-12-01

Study Record Updates

Study Start Date2018-06-05
Study Completion Date2026-12-01

Terms related to this study

Additional Relevant MeSH Terms

  • Prostate Cancer